The GST Council has cleared a notable change in the indirect tax framework that will allow pharmaceutical companies to claim input tax credit, or ITC, on free samples distributed to doctors and hospitals, as well as on goods that are destroyed after expiry, from the next fiscal year. The decision marks a meaningful shift in how the tax system treats inventory that does not generate direct sales revenue but is nonetheless integral to pharmaceutical marketing, compliance and product lifecycle management.
The changes in the GST law and rules will take effect from FY28, giving companies and tax administrators time to prepare for the revised compliance architecture. For an industry that routinely distributes samples to build physician familiarity and must also destroy unsold or expired stock under strict regulatory controls, the move removes a persistent tax inefficiency that has long been viewed as inconsistent with the sector's operating model.
Tax Relief For Pharma
Until now, the inability to claim ITC on such supplies effectively meant that companies absorbed the GST cost on products that were not sold in the conventional sense. In the pharmaceutical business, free samples are a standard commercial tool, used to introduce new formulations, support treatment initiation and expand market penetration. Separately, expiry-related destruction is not discretionary waste but a necessary consequence of shelf-life constraints, quality standards and patient safety requirements. By permitting ITC in these cases, the Council has acknowledged that the tax burden should not fall on inventory losses that are either mandated by business practice or unavoidable under regulatory norms.
The change is likely to be welcomed by large drugmakers, contract manufacturers and companies with broad product portfolios, particularly those operating in highly competitive therapeutic categories. It may also improve working capital efficiency, since tax credits can now be set off against output liabilities rather than being locked into unrecoverable costs. For a sector that faces tight price controls in several segments and rising compliance costs across manufacturing and distribution, even incremental tax relief can have a material effect on margins.
Compliance And Pricing Impact
The policy shift also has broader implications for pricing discipline and tax administration. By reducing the embedded tax cost of samples and expired goods, the government is effectively narrowing a distortion that had made pharmaceutical accounting more complex than that of many other sectors. Companies will still need robust documentation to establish eligibility for credit, especially in relation to stock destruction, batch tracking and proof of disposal. That means the benefit will depend not only on the legal change itself but also on the quality of implementation and record-keeping.
From a fiscal policy perspective, the decision reflects a more calibrated approach to GST design, one that seeks to balance revenue protection with sector-specific realities. The pharmaceutical industry is unusual in that product expiry is an operational certainty, not an exceptional event. Free samples, meanwhile, are a recognised part of market development and medical engagement. Treating both categories as ineligible for credit had long been criticised by industry participants as a tax on legitimate business expenditure rather than on consumption.
Next Fiscal Year Shift
The timing of the reform is also significant. With the changes slated to become effective from the next fiscal year, companies have a window to adjust systems, update internal controls and align supply-chain processes with the revised rules. That transition period should help reduce disputes and ensure that the benefit is captured cleanly once the new provisions come into force.
The Council's decision comes at a time when policymakers are under pressure to simplify indirect taxation without undermining collections. While the immediate revenue impact is likely to be limited, the move could improve the overall coherence of GST treatment in the healthcare supply chain. It also signals that the tax regime is gradually moving toward a more nuanced recognition of sector-specific business practices, rather than applying a one-size-fits-all approach to all inventory movements.
For pharmaceutical companies, the practical effect is straightforward: a lower tax cost on products that are given away or destroyed for legitimate reasons, and a modest but meaningful improvement in cash flow. For the broader economy, the decision is another example of GST policy being fine-tuned to reduce friction in compliance-heavy industries while preserving the core architecture of the tax system.